Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Durbin responds

Durbin responds

I would like to share with your subscribers a further examination of the impact of my Prescription Drug Consumer Protection Act of 1993 on the biotechnology industry.

My legislation does not make explicit distinctions between

Read the full 369 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE